{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:06:53Z","timestamp":1778818013176,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009542","name":"Limburg Sterk Merk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009550","name":"Universiteit Hasselt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejoncologynursing.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Oncology Nursing"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ejon.2023.102278","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T17:36:24Z","timestamp":1676050584000},"page":"102278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Evaluation of a novel skin care product for the management of chemotherapy\u2013related dermatologic toxicities: A quasi-experimental study"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-1581","authenticated-orcid":false,"given":"Jolien","family":"Robijns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy","family":"Lodewijckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marith\u00e9","family":"Claes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Tuts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Lenaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Requil\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy","family":"Luyten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanda","family":"Verheezen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Joosens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Mebis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejon.2023.102278_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000051809","article-title":"Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2,242 dermatological outpatients","volume":"204","author":"Abeni","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.ejon.2023.102278_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40257-022-00705-z","article-title":"Oncodermatology: advancing the science and care of cancer patients and survivors","volume":"23","author":"Bang","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ejon.2023.102278_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/CMAR.S52256","article-title":"Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel","volume":"5","author":"Bensadoun","year":"2013","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ejon.2023.102278_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00403-010-1073-0","article-title":"Dimensions of patient needs in dermatology: subscales of the patient benefit index","volume":"303","author":"Blome","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.ejon.2023.102278_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.abd.2020.01.001","article-title":"Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel","volume":"95","author":"Cury-Martins","year":"2020","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.ejon.2023.102278_bib6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/EDBK_289911","article-title":"Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy","volume":"40","author":"Deutsch","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejon.2023.102278_bib7","series-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2020"},{"key":"10.1016\/j.ejon.2023.102278_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijwd.2019.10.003","article-title":"Dermatologic conditions in women receiving systemic cancer therapy","volume":"5","author":"Ferreira","year":"2019","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.ejon.2023.102278_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.ejon.2023.102278_bib10","first-page":"545","article-title":"Skin care management in cancer patients: an evaluation of quality of life and tolerability","volume":"19","author":"Haley","year":"2011","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ejon.2023.102278_bib11","doi-asserted-by":"crossref","first-page":"3ss","DOI":"10.36849\/JDD.6229","article-title":"US cutaneous oncodermatology management (USCOM): a practical algorithm","volume":"20","author":"Lacouture","year":"2021","journal-title":"J. Drugs Dermatol. JDD"},{"key":"10.1016\/j.ejon.2023.102278_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejon.2023.102278_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejon.2023.102278_bib14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2165\/00128071-200304110-00005","article-title":"Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders","volume":"4","author":"Loden","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ejon.2023.102278_bib15","first-page":"4931","article-title":"Supportive oncodermatology-a narrative review of its utility and the way forward","volume":"29","author":"Long","year":"2021","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ejon.2023.102278_bib16","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.2147\/OTT.S155438","article-title":"Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy","volume":"11","author":"Luftner","year":"2018","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejon.2023.102278_bib17","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3344","article-title":"Mechanisms and management of itch in dry skin","volume":"100","author":"Moniaga","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.ejon.2023.102278_bib18","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"key":"10.1016\/j.ejon.2023.102278_bib19","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3417","article-title":"\"DLQI seems to be 'action', and skindex-29 seems to be 'emotion'\": qualitative study of the perceptions of patients with psoriasis or eczema on two common dermatology-specific quality of life measures","volume":"100","author":"Paudyal","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.ejon.2023.102278_bib20","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/09546634.2019.1607024","article-title":"Dry skin management: practical approach in light of latest research on skin structure and function","volume":"31","author":"Proksch","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.ejon.2023.102278_bib21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1610-0387.2005.05068.x","article-title":"The management of dry skin with topical emollients--recent perspectives","volume":"3","author":"Proksch","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ejon.2023.102278_bib22","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/j.1468-3083.2012.04466.x","article-title":"The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients","volume":"27","author":"Ra","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ejon.2023.102278_bib23","first-page":"203","article-title":"Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs","volume":"71","author":"Reyes-Habito","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejon.2023.102278_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","article-title":"Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic","volume":"14","author":"Rosen","year":"2013","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ejon.2023.102278_bib25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaad.2020.08.005","article-title":"Restorative oncodermatology: diagnosis and management of dermatologic sequelae from cancer therapies","volume":"85","author":"Rossi","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejon.2023.102278_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696.ch1","article-title":"Introduction","author":"Rubin","year":"1987","journal-title":"Multiple Imputation for Nonresponse in Surveys"},{"key":"10.1016\/j.ejon.2023.102278_bib27","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/jid.2011.191","article-title":"Interpretation of skindex-29 scores","volume":"131","author":"Sampogna","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejon.2023.102278_bib28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.soncn.2017.08.001","article-title":"The role of oncodermatology in the care of patients receiving cancer therapy","volume":"33","author":"Skripnik Lucas","year":"2017","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.ejon.2023.102278_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.therap.2021.12.006","article-title":"Dermatological adverse drug reactions of anticancer drugs: international data of pharmacovigilance: VigiBase(R)","volume":"77","author":"Strumia","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.ejon.2023.102278_bib30","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-6-6","article-title":"Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study","volume":"9","author":"Suh Oh","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.ejon.2023.102278_bib31","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s13555-022-00685-2","article-title":"An emollient plus balm is useful for the management of xerosis in patients treated for cancer: a real-world, prospective, observational, multicenter study","volume":"12","author":"Vendrely","year":"2022","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ejon.2023.102278_bib32","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1188\/20.CJON.561-565","article-title":"Skin toxicity: clinical summary of the ONS guidelines for cancer treatment-related skin toxicity","volume":"24","author":"Wiley","year":"2020","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.ejon.2023.102278_bib33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1188\/20.ONF.539-556","article-title":"ONS guidelines for cancer treatment-related skin toxicity","volume":"47","author":"Williams","year":"2020","journal-title":"Oncol. Nurs. Forum"},{"key":"10.1016\/j.ejon.2023.102278_bib34","first-page":"115","article-title":"Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer","volume":"6","author":"Wohlrab","year":"2014","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejon.2023.102278_bib35","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2340\/00015555-3296","article-title":"Skin barrier damage and itch: review of mechanisms, topical management and future directions","volume":"99","author":"Yosipovitch","year":"2019","journal-title":"Acta Derm. Venereol."}],"container-title":["European Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388923000121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388923000121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T20:24:46Z","timestamp":1761423886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1462388923000121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":35,"alternative-id":["S1462388923000121"],"URL":"https:\/\/doi.org\/10.1016\/j.ejon.2023.102278","relation":{},"ISSN":["1462-3889"],"issn-type":[{"value":"1462-3889","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of a novel skin care product for the management of chemotherapy\u2013related dermatologic toxicities: A quasi-experimental study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejon.2023.102278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102278"}}